‘Pay-for-delay’ deals on the wane, says FTC

Pharmaceutical companies have entered into fewer ‘pay-for-delay’ patent settlements since the US Supreme Court said such agreements could violate anti-competition laws, a report has claimed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

‘Considerable increase’ in pay-for-delay settlements: FTC report

24 May 2019 The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.

Americas

Pay-for-delay settlements fall for second year: FTC report

6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

Americas

FTC welcomes Supreme Court 'pay-for-delay' ruling

25 July 2013 The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

‘Pay-for-delay’ deals on the wane, says FTC

More on this story

Editor's picks

Editor's picks

More features